Sarepta eyes Elevidys sales comeback with positive Phase III data
Following a tough 2025 for Sarepta, the biotech has posted positive, long-term Phase III data on its Duchenne muscular dystrophy…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Bausch Health’s new formulation of Xifaxan fails pair of Phase III trials
A new formulation of Bausch Health’s Xifaxan (rifaximin) has failed to demonstrate efficacy in two Phase III studies in hepatic…
-
ImmunityBio’s glioblastoma regimen boosts survival in mid-stage study
ImmunityBio’s immunotherapy combination regimen has demonstrated its early potential during a mid-stage trial in patients with glioblastoma and severe lymphopenia.…
-
Sanofi’s Dupixent successor heads to regulators after Phase III success
Sanofi has debuted the long-awaited results from two Phase III studies of its potential Dupixent (dupilumab) successor, amlitelimab, in atopic…
-
Genespire to take rare disease gene therapy to clinic in 2026
Rare disease biotech Genespire is looking to take its single-dose gene therapy – GENE202 – to the clinic in 2026,…
-
Moderna and MSD’s cancer vaccine plus Keytruda boosts RFS in melanoma study
A combination of Moderna and MSD's personalised cancer vaccine, intismeran autogene, and MSD’s stalwart oncology drug, Keytruda (pembrolizumab), has significantly…
-
Speech biomarkers offer new lease of life to patient experience and trial retention
Biomarkers remain a critical measurement in almost every clinical trial, with this type of data facilitating the accurate characterisation of…
-
Ocugen sets sights on Phase III after GA gene therapy win
Ocugen has posted positive results for its lead investigational gene therapy, OCU410, in geographic atrophy (GA) secondary to dry age-related…
-
FDA and EMA release collaborative AI framework for drug development
In a bid to optimise the use of AI in drug development, US and European regulators have banded together to…
-
Akeso’s PD-1/CTLA-4 bispecific trumps chemo in frontline gastric cancer
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in…